Pilot Analysis of the Effects of IFN alpha-2b Upon the Molecular Profile of Regional Lymph Nodes in Melanoma Patients With and Without Tumor-Involved Sentinel Lymph Nodes.

Trial Profile

Pilot Analysis of the Effects of IFN alpha-2b Upon the Molecular Profile of Regional Lymph Nodes in Melanoma Patients With and Without Tumor-Involved Sentinel Lymph Nodes.

Discontinued
Phase of Trial: Phase 0

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Interferon alpha-2b (Primary) ; Interferon alpha-2b (Primary) ; Peginterferon alfa-2b (Primary)
  • Indications Malignant melanoma
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 03 Aug 2017 Status changed from recruiting to discontinued.
    • 08 Jun 2016 Planned End Date changed from 1 Apr 2016 to 1 Apr 2019.
    • 08 Jun 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top